The present invention provides methods for improving the pharmacokinetics of protease inhibitors and protease inhibitor precursors and pharmaceutical composition comprising protease inhibitors or protease inhibitor precursors of formula I and a cytochrome P450 monooxigenase inhibitor;
when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R
1
may be, for example, (HO)
2
P(O)—, (NaO)
2
P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R
2
and R
3
are as defined herein.
本发明提供了一种改善蛋白酶抑制剂和蛋白酶抑制剂前体的药代动力学的方法,以及包含公式I的蛋白酶抑制剂或蛋白酶抑制剂前体和细胞色素P450单加氧酶
抑制剂的制药组合物;当公式I的化合物包括
氨基团时,其药学上可接受的
铵盐可以是R1,例如(HO)2P(O)—,(NaO)2P(O)—,烷基-CO—或环烷基-CO—,其中X可以是F、Cl和Br,R2和R3如本文所定义。